| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2004.08.050 |
| P698 | PubMed publication ID | 15670887 |
| P50 | author | Andrew James McMichael | Q21165187 |
| P2093 | author name string | Tomás Hanke | |
| Sally A Sharpe | |||
| Michael J Dennis | |||
| Lindsey A J Powell | |||
| Lorraine McLoughlin | |||
| Steven J Crome | |||
| P2860 | cites work | Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. | Q34467405 |
| Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses | Q35234767 | ||
| MVA as a vector for vaccines against HIV-1. | Q35851793 | ||
| Nonreplicating vaccinia vector efficiently expresses recombinant genes | Q37299518 | ||
| Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge | Q37358213 | ||
| Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine | Q39589039 | ||
| Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine | Q41039759 | ||
| Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells | Q41064284 | ||
| Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line | Q41076591 | ||
| Anti-major histocompatibility complex antibody responses to simian B cells do not protect macaques against SIVmac infection | Q41098949 | ||
| Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence | Q41684943 | ||
| Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults | Q44939076 | ||
| A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans | Q45661091 | ||
| Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration | Q45723808 | ||
| Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers | Q45723913 | ||
| Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya | Q45730049 | ||
| Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity | Q45736005 | ||
| Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. | Q45737034 | ||
| Real-time TaqMan PCR as a specific and more sensitive alternative to the branched-chain DNA assay for quantitation of simian immunodeficiency virus RNA. | Q45738726 | ||
| Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya | Q46958770 | ||
| Comparison of the efficacy of early versus late viral proteins in vaccination against SIV | Q56880151 | ||
| Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals | Q57081485 | ||
| Studies on poxvirus infections in irradiated animals | Q72861146 | ||
| Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime | Q74601718 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 8 | |
| P304 | page(s) | 1507-1514 | |
| P577 | publication date | 2005-02-01 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice | |
| P478 | volume | 23 |
| Q36824066 | A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector. |
| Q33945612 | A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice |
| Q37502368 | Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice |
| Q45423126 | Altered primary CD8+ T cell response to a modified virus Ankara(MVA)-vectored vaccine in the absence of CD4+ T cell help |
| Q27008256 | Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination |
| Q80207648 | Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine |
| Q35113347 | Different patterns of expansion, contraction and memory differentiation of HIV-1 Gag-specific CD8 T cells elicited by adenovirus type 5 and modified vaccinia Ankara vaccines |
| Q56564203 | Distribution and absence of generalized lesions in mice following single dose intramuscular inoculation of the vaccine candidate MVA-MERS-S |
| Q33635050 | Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice |
| Q35857708 | Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination |
| Q38176419 | Environmental risk assessment of clinical trials involving modified vaccinia virus Ankara (MVA)-based vectors |
| Q45325213 | Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps? |
| Q34017475 | In vitro host range, multiplication and virion forms of recombinant viruses obtained from co-infection in vitro with a vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus isolate |
| Q39876175 | Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN-gamma ELISPOT assay |
| Q34142869 | Induction of human immunodeficiency virus type 1-specific T cells by a bluetongue virus tubule-vectored vaccine prime-recombinant modified virus Ankara boost regimen |
| Q82044309 | Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers |
| Q40497816 | MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults |
| Q30418570 | Novel viral vectored vaccines for the prevention of influenza |
| Q44604745 | Pharmacokinetics and risk evaluation of DNA vaccine against Schistosoma japonicum |
| Q36889718 | Quantitative real-time PCR study on persistence of pDNA vaccine pVax-Hsp60 TM814 in beef muscles |
| Q45407829 | Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy |
| Q36225504 | Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal. |
| Q80861378 | Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine |
| Q43969171 | Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects |
| Q35751946 | Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1. |
| Q51989059 | Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T cell responses. |
Search more.